Recurrent hepatitis C virus infection post liver transplantation: Impact of choice of calcineurin inhibitor

Transplant International

Volumn 26, Issue 4, 2013, Pages 358-372

  Duvoux, Christophe ^a   Firpi, Roberto ^b   Grazi, Gian L ^c   Levy, Gary ^d   Renner, Eberhard ^e   Villamil, Federico ^f  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY OF FLORIDA   (United States)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

calcineurin inhibitor; cyclosporine A; HCV; liver transplantation

Indexed keywords

ALISPORIVIR; CALCINEURIN INHIBITOR; CYCLOSPORIN A; PEGINTERFERON ALPHA; RIBAVIRIN; TACROLIMUS;

DRUG EFFICACY; DRUG SAFETY; FIBROGENESIS; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

CALCINEURIN; CYCLOSPORINE; DIABETES MELLITUS; FIBROSIS; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN RESISTANCE; LIVER TRANSPLANTATION; RECURRENCE; VIRUS REPLICATION;

EID: 84875382444     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12065     Document Type: Review

References (123)

1. US Department of Health & Human Services. OPTN/SRTR 2008 Annual Report. Chapter IV. Liver and intestine transplantation in the United States 1998-2007. Available at http://optn.transplant.hrsa.gov/ar2008/chapter-iv-AR-cd. htm?cp=5. Last updated 2008.
2. 0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632.
3. Levy G, Grazi GL, Sanjuan F, et al,. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12: 1464.
4. Irish WD, Arcona S, Bowers D, Trotter JF,. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 1676.
5. Dawwas MF, Gimson AE, Lewsey JD, Copley LP, van der Meulen JH, on behalf of the UK and Ireland Liver Transplant Audit. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut 2007; 56: 1606.
6. Angelico M, Cillo U, Fagiuoli S, et al,. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155.
7. Garcia-Retortillo M, Forns X, Feliu A, et al,. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680.
8. Saraf N, Fiel MI, Deboccardo G, Emre S, Schiano TD,. Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl 2007; 13: 913.
9. Duvoux C, Pawlotsky J-M, Cherqui D, Julien M, Duval J, Dhumeaux D,. Diagnosis of HCV recurrence after liver transplantation using branched DNA assay for HCV RNA quantitation. Transplantation 1994; 58: 953.
10. Berenguer M, Lõpez-Labrador FX, Wright TL,. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666.
11. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36.
12. Berenguer M, Ferrell L, Watson J, et al,. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
13. Firpi RJ, Clark V, Soldevila-Pico C, et al,. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063.
14. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
15. Berenguer M, Prieto M, San Juan F, et al,. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
16. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al,. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125.
17. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al,. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240.
18. Wiesner RH, Sorrell M, Villamil F, the International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society Expert Panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9 (Suppl 3): S1.
19. Foxton MR, Quaglia A, Muiesan P, et al,. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922.
20. Levitsky J, Doucette K, the AST Infectious Diseases Community of Practice. Viral hepatitis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S116.
21. Gallegos-Orozco JF, Yosephy A, Noble B, et al,. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872.
22. Watt K, Veldt B, Charlton M,. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009; 9: 1707.
23. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335.
24. Burra P,. Hepatitis C. Semin Liver Dis 2009; 29: 53.
25. Selzner N, Renner EL, Selzner M, et al,. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214.
26. Picciotto FP, Tritto G, Lanza AG, et al,. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459.
27. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
28. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al,. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000.
29. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207.
30. Hézode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839.
31. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827.
32. Coilly A, Roche B, Botta-Fridlund D, et al,. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol 2012; 56 (Suppl 2): S21.
33. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL,. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578.
34. Haddad E, McAlister V, Renouf E, Malthaner R, Kjaer MS, Gluud LL,. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; Art No. CD005161.
35. Fung J, Abu-Elmagd K, Jain A, et al,. A randomized trial of primary liver transplantation under immunosuppression with FK 506 versus cyclosporine. Transplant Proc 1991; 23: 2977.
36. McMaster P,. Patient and graft survival in the European Multicentre Liver Study-FK 506 vs cyclosporin A. Transpl Int 1994; 7 (Suppl 1): S32.
37. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
38. Berenguer M, Aguilera V, San Juan F, et al,. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204.
39. O'Grady JG, Hardy P, Burroughs AK, Elbourne D, The UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137.
40. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21.
41. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K,. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282.
42. Nakagawa M, Sakamoto N, Enomoto N, et al,. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42.
43. Firpi RJ, Zhu H, Morelli G, et al,. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51.
44. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K,. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 2006; 343: 879.
45. Siekierka JJ, Staruch MJ, Hung SHY, Sigal NH,. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol 1989; 143: 1580.
46. Watashi K, Shimotohno K,. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007; 17: 245.
47. Yang F, Robotham JM, Grise H, et al,. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog 2010; 6: e1001118.
48. Gallay PA,. Cyclophilin inhibitors. Clin Liver Dis 2009; 13: 403.
49. Flisiak R, Pawlotsky J-M, Crabbé R, et al,. Once daily alisporivir (Deb025) plus PegIFNalpha2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients. Abstract presented at the International Liver Congress 46th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany, 30 March-3 April, 2011.
50. Kneteman NM, Asthana S, Lewis J, et al,. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection. Liver Transpl 2012; 18: 38.
51. Martin P, Busuttil RW, Goldstein RM, et al,. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 1258.
52. Berenguer M, Aguilera V, Prieto M, et al,. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762.
53. Kim RD, Mizuno S, Sorensen JB, Schwartz JJ, Fujita S,. Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation. Dig Dis Sci 2012; 57: 568.
54. Carriõn JA, Navasa M, García-Retortillo M, et al,. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746.
55. Fernández I, Meneu JC, Colina F, et al,. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805.
56. Berenguer M, Aguilera V, Prieto M, et al,. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738.
57. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M,. Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567.
58. ReViS-TC Study Group. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334.
59. Rabie R, Mumtaz K, Renner EL,. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: A systematic review and meta-analysis. Liver Transpl 2013; 19: 36.
60. Cescon M, Grazi GL, Cucchetti A, et al,. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782.
61. Rayhill SC, Barbeito R, Katz D, et al,. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc 2006; 38: 3625.
62. Berenguer M, Palau A, Fernandez A, et al,. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067.
63. Firpi RJ, Soldevila-Pico C, Morelli GG, et al,. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196.
64. Lodato F, Berardi S, Gramenzi A, et al,. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450.
65. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN,. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53.
66. Dumortier J, Scoazec J-Y, Chevallier P, Boillot O,. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
67. Oton E, Barcena R, Moreno-Planas JM, et al,. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose Peg-interferon and ribavirin. Am J Transplant 2006; 6: 2348.
68. Bitetto D, Falleti E, Fornasiere E, Belli L, Vigano R, Fagiuoli S,. Interaction between cyclosporine and recipient il-28b rs12979860 c > t genetic polymorphisms in the achievement of sustained viral response for recurrent hepatitis C. J Hepatol 2012; 56: S37, 85 (abstract).
69. Calmus Y, Samuel D, Pageaux G, et al,. Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: 18-month report. Hepatology 2010; 44: 189A, 4 (abstract).
70. Giusto M, Rodriguez M, Navarro L, et al,. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transpl 2011; 17: 1318.
71. Gordon F, Poordad F, Neff GW, et al,. Baseline, donor, and on-treatment predictors of sustained virologic response in patients treated for recurrent hepatitis C following orthotopic liver transplant: subanalysis of the PROTECT study. Hepatology 2010; 52: 754A, 905 (abstract).
72. Ikegami T, Taketomi A, Soejima Y, et al,. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. Transplant Proc 2009; 41: 4246.
73. Jiménez-Pérez M, Sáez-Gõmez AB, Pérez-Daga JA, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-Lõpez JM,. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. Transplant Proc 2010; 42: 666.
74. Roche B, Sebagh M, Canfora ML, et al,. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766.
75. Vero V, Senzolo M, Pasulo L, Ponziani F, Raffaella V, Marino M,. Is the primary immunosuppressive drug (cyclosporine or tacrolimus) playing a role on the response to antiviral treatment for post-transplant HCV-recurrence? Liver Transpl 2011; 17: S97.
76. Sugawara Y, Kaneko J, Makuuchi M,. Cyclosporin A for treatment of hepatitis C virus after liver transplantation [letter]. Transplantation 2006; 82: 579.
77. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317.
78. Zekry A, Bishop GA, Bowen DG, et al,. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002; 8: 292.
79. Dharancy S, Podevin P, Aoudjehane L, et al,. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Transplantation 2007; 83: 906.
80. Conti F, Calmus Y, Rouer E, et al,. Increased expression of interleukin-4 during liver allograft rejection. J Hepatol 1999; 30: 935.
81. Aoudjehane L, Pissaia Jr A, Scatton O, et al,. Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway. Lab Invest 2008; 88: 973.
82. Ikeda H, Fujiwara K,. Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. Hepatology 1995; 21: 1161.
83. Nakamuta M, Kohjima M, Fukushima M, et al,. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc 2005; 37: 4598.
84. Pissaia Jr A, Aoudjehane L, Ben Othman S, et al,. Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor β on human intrahepatic fibroblasts cultured in vitro. Transplant Proc 2010; 42: 4343.
85. Povero D, Busletta C, Novo E, et al,. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010; 25: 1075.
86. Tannapfel A, Kohlhaw K, Ebelt J, et al,. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation 1999; 67: 1079.
87. Bantel H, Lügering A, Heidemann J, et al,. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078.
88. Broekemeier KM, Dempsey ME, Pfeiffer DR,. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989; 264: 7826.
89. Kim JS, Qian T, Lemasters JJ,. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. Gastroenterology 2003; 124: 494.
90. Okamoto T, Hitomi Y, Hara A,. The protective effect of cyclosporine A on anti-Fas antibody-induced hepatitis in mice. Jpn J Pharmacol 1999; 79: 485.
91. Moriuchi H, Kamohara Y, Eguchi S, et al,. Diverse effects of FK506 on the apoptosis of hepatocytes and infiltrating lymphocytes in an allografted rat liver. J Surg Res 2011; 167: 131.
92. Duvoux C, Mennecier D, Pageaux GP, Conti F, Roudot-Thoraval F, Dhumeaux D,. Immunosuppression with tacrolimus and absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus (HCV) graft reinfection. Abstract 2652 presented at the International Society of Transplantation Congress, 2002.
93. Villamil F, Levy G, Grazi GL, et al,. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc 2006; 38: 2964.
94. van der Laan LJ, Thomas RC, Zondervan PE, et al,. The effect of calcineurin inhibitor usage on hepatic fibrosis progression in HCV-positive liver transplant recipients: a two-centre study. Liver Transpl 2007; 13: S152, 317 (abstract).
95. Cisneros L, Londoño MC, Blasco C, et al,. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl 2007; 13: 1017.
96. O'Leary JG, Trotter JF, Neri MA, et al,. Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Bayl Univ Med Cent) 2011; 24: 187.
97. Bahr MJ, Beckermann JGP, Rifai K, et al,. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc 2005; 37: 1703.
98. Hunt J, Gordon FD, Lewis WD, et al,. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001; 7: 1056.
99. van der Laan LJ, Hudson M, McPherson S, et al,. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplant Proc 2010; 42: 4573.
100. Johnson MW, Washburn WK, Freeman RB, et al,. Hepatitis C viral infection in liver transplantation. Arch Surg 1996; 131: 284.
101. Oton E, Barcena R, Castillo M, et al,. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Transplant Proc 2006; 38: 2499.
102. Cimsit B, Assis D, Caldwell C, et al,. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc 2011; 43: 905.
103. White DL, Ratziu V, El-Serag HB,. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831.
104. Saliba F, Lakehal M, Pageaux GP, et al,. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007; 13: 136.
105. Hanouneh IA, Feldstein AE, McCullough AJ, et al,. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287.
106. Veldt BJ, Poterucha JJ, Watt KDS, et al,. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406.
107. Romero-Gõmez M, Del Mar Viloria M, Andrade RJ, et al,. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636.
108. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN,. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009; 54: 2699.
109. Hurtova M, Fourti M, Medjahed N, et al,. Early virological response and absence of diabetes are associated with sustained virological response to hepatitis C treatment after liver transplantation in patients with cyclosporine A based immunosuppression. Hepatology 2008; 48 (Suppl 1): 581A, 614 (abstract).
110. Dumortier J, Bernard S, Bouffard Y, Boillot O,. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006; 12: 659.
111. Rendina M, Rossi G, D'Amico D, et al,. Conversion to cyclosporine therapy induces significant benefits in liver transplant recipients on tacrolimus with new onset diabetes: the DIALIVER study. Am J Transplant 2009; 9 (Suppl 2): 328, 471 (abstract).
112. Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, et al,. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transplant Proc 2008; 40: 2994.
113. Golden-Mason L, Rosen HR,. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl 2006; 12: 363.
114. + response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117: 926.
115. + innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008; 14: 31.
116. Kimball P, Verbeke S, Shiffman M,. HCV core protein augments cyclosporine immunosuppression. Transplant Proc 2005; 37: 652.
117. + regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062.
118. Miroux C, Moralès O, Carpentier A, et al,. Inhibitory effects of cyclosporine on human regulatory T cells in vitro. Transplant Proc 2009; 41: 3371.
119. + regulatory T cells by rabbit anti-thymocyte globulins. Clin Exp Immunol 2010; 161: 364.
120. 2 monitoring: a European consensus. Transpl Int 2005; 18: 768.
121. Testa G, Crippin JS, Netto GJ, et al,. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553.
122. Sheiner PA, Schwartz ME, Mor E, et al,. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
123. Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R,. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. Transplant Proc 2003; 35: 612.